Table 2.

Comparison of patient characteristics with CD68 and CD163 IHC expression in the entire cohort

	CD68low		CD68high		P	CD163low		CD163high		P
	n	%	n	%		n	%	n	%
Total	178		109			168		119
Age (≥ 45 y)
No	157	88	83	76	< .01	147	88	93	78	.04
Yes	21	12	26	24		21	13	26	22
Sex
Female	82	46	44	40	.35	76	45	50	42	.59
Male	96	54	65	60		92	55	69	58
Stage 4 disease
No	132	74	84	77	.58	129	77	87	73	.48
Yes	46	26	25	23		39	23	32	27
Albumin (< 4 g/dL)*
No	56	31	31	28	.62	45	27	42	35	.11
Yes	117	66	74	68		118	70	73	61
Unknown	5	3	4	4		5	3	4	3
Hemoglobin (< 10.5 g/dL)*
No	140	79	86	79	.97	136	81	90	76	.39
Yes	28	16	17	16		24	14	21	18
Unknown	10	6	6	6		8	5	8	7
WBC count (≥ 15 000/mm3)*
No	135	76	91	83	.10	129	77	97	82	.18
Yes	30	17	11	10		28	17	13	11
Unknown	13	7	7	6		11	7	9	8
Lymphocyte count (< 600/mm3 or < 8%)*
No	157	88	94	86	.19	148	88	103	87	.32
Yes	9	5	10	9		9	5	10	8
Unknown	12	7	5	5		11	7	6	5
IPS (≥ 3)*
No	120	67	69	63	.54	114	68	75	63	.45
Yes	58	33	39	36		54	32	43	36
Unknown	0	0	1	1		0	0	1	1
Histologic subtype*
Nodular sclerosis	152	85	71	65	< .01	141	84	82	69	< .01
Mixed cellularity	11	6	27	25		13	8	25	21
Lymphocyte rich	5	3	3	3		6	4	2	2
Lymphocyte depleted	0	0	1	1		0	0	1	1
Unclassified	10	6	7	6		8	5	9	8
Treatment received
ABVD	88	49	56	51	.75	82	49	62	52	.58
Stanford V	90	51	53	49		86	51	57	48
EBER ISH
Positive	15	8	34	31	< .01	20	12	29	24	< .01
Negative	163	92	75	69		148	88	90	76

P values compare CD68^low with CD68^high, and CD163^low with CD163^high patients.

^*Pearson χ² test was performed with unknown or unclassified cases excluded.